Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

Feb 16, 2017, 08:30 ET New England Journal of Medicine Publishes Five-Year Data from Ethicon-Funded STAMPEDE Study

Ethicon* announced today the New England Journal of Medicine (NEJM) publication of the final five-year data from the Ethicon-funded STAMPEDE...


Feb 16, 2017, 08:08 ET U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has...


Feb 16, 2017, 08:00 ET Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery

Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics, today announced...


Feb 16, 2017, 07:30 ET Denovo Biopharma plans to launch a Global Phase 3 Trial of DB102 (Enzastaurin) in Diffuse Large B-cell Lymphoma

Denovo Biopharma LLC, a leading company in precision medicine announces the plan to initiate a biomarker driven global phase 3 clinical trial for...


Feb 16, 2017, 07:15 ET Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation and Improves Survival in a High-Pathogen Avian Influenza Preclinical Study

Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focusing on developing aerosolized KL4 surfactant therapies for respiratory...


Feb 16, 2017, 02:20 ET New Study Published in Lancet Respiratory Medicine Highlights QIAGEN's QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants

Results Suggest Benefits of Quantitative Screening of Young Children in Countries With High TB Burden QIAGEN N.V. (NASDAQ: QGEN; Frankfurt...


Feb 16, 2017, 01:30 ET City of Hope to Manufacture NurOwn® for Brainstorm's Phase 3 ALS Clinical Trial

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced...


Feb 15, 2017, 19:00 ET Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that pharmacokinetics (PK) and pharmacodynamics (PD) data comparing the...


Feb 15, 2017, 18:30 ET Le vaccin PfSPZ de Sanaria offre un niveau élevé de protection contre les infections paludiques naturelles au Mali

Dans un rapport publié aujourd'hui dans The Lancet Infectious Diseases, intitulé « Safety and efficacy of PfSPZ Vaccine against Plasmodium...


Feb 15, 2017, 18:30 ET La vacuna PfSPZ de Sanaria proporciona protección eficaz contra las infecciones de malaria naturales en Mali

En un informe publicado hoy a través de The Lancet Infectious Diseases (Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via...


Feb 15, 2017, 18:30 ET Impfstoff PfSPZ von Sanaria bietet signifikanten Schutz vor Malariainfektionen in Mali

In einem heute in der wissenschaftlichen Fachzeitschrift The Lancet Infectious Diseases veröffentlichten Bericht (Safety and efficacy of...


Feb 15, 2017, 17:56 ET Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase...


Feb 15, 2017, 13:29 ET Hospital Readmissions Reduced Significantly Using a Novel Heart Failure Protocol at New York City Nursing Homes

A novel protocol that remotely monitors congestive heart failure patients in skilled nursing facilities and uses automated alerts to notify...


Feb 15, 2017, 13:11 ET Autism Center at Rush Seeking Participants for Social Skills Study

Chicagoland families and providers with children on the autism spectrum are invited to enroll in a groundbreaking social skills study. The Autism...


Feb 15, 2017, 13:00 ET Sanaria's PfSPZ-CVac Vaccine Achieves High Level Protection Against Malaria in Clinical Trial

In a report published today in Nature, (Sterile protection against human malaria by chemoattenuated PfSPZ vaccine) investigators from the...


Feb 15, 2017, 11:01 ET Biosensors gibt Aufnahme des ersten Patienten in die US-amerikanische Schlüsselstudie BioFreedom "LEADERS FREE II" bekannt

Biosensors International Group, Ltd. ("Biosensors" oder das "Unternehmen"), ein Entwickler, Hersteller und Vermarkter innovativer medizinischer...


Feb 15, 2017, 10:42 ET FDA Approval Granted for BIOTRONIK's Ultra-Thin PRO-Kinetic Energy Cobalt Chromium Coronary Stent System

PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from BIOTRONIK gained FDA approval utilizing results from the BIOHELIX-I clinical...


Feb 15, 2017, 10:35 ET Blue Horizon International team to attend Clinical Trials Masterclass in New York

Brian Mehling, M.D. and Marina Manvelyan, Ph.D., will attend a three-day long Masterclass in Clinical Trials and Medicine Development from February...


Feb 15, 2017, 09:45 ET Biosensors anuncia reclutamiento del primer paciente en el nuevo ensayo BioFreedom en EE.UU. - "LEADERS FREE II"

Biosensors International Group, Ltd. ("Biosensors" o la "Compañía"), un desarrollador, fabricante y comercializador de innovadores dispositivos...


Feb 15, 2017, 09:15 ET TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based...